Rocket Pharma's Danon Disease Trial Resumes After FDA Lift!
Rocket Pharma's RP-A501 Danon disease trial resumed after FDA lifted hold due to patient death. Shares surged. It will use a lower dose & modified regimen. Signals FDA support for gene therapy despite investor wariness & other patient deaths, like Sarepta's and Neurogene's.